ES2070994T3 - Profarmaco de dopamina. - Google Patents

Profarmaco de dopamina.

Info

Publication number
ES2070994T3
ES2070994T3 ES90200937T ES90200937T ES2070994T3 ES 2070994 T3 ES2070994 T3 ES 2070994T3 ES 90200937 T ES90200937 T ES 90200937T ES 90200937 T ES90200937 T ES 90200937T ES 2070994 T3 ES2070994 T3 ES 2070994T3
Authority
ES
Spain
Prior art keywords
profarmaco
dopamine
salts
compound
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90200937T
Other languages
English (en)
Inventor
Cesare Casagrande
Francesco Santangelo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zambon Group SpA
Zambon SpA
Original Assignee
Zambon Group SpA
Zambon SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT8920209A external-priority patent/IT1229853B/it
Priority claimed from IT8920210A external-priority patent/IT1229854B/it
Application filed by Zambon Group SpA, Zambon SpA filed Critical Zambon Group SpA
Application granted granted Critical
Publication of ES2070994T3 publication Critical patent/ES2070994T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/12—Esters of phosphoric acids with hydroxyaryl compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE DESCRIBEN UN ESTER L-DIHIDROXIFENILOALANINA MONOFOSFORADO DE FORMULA (EN DONDE EL *, R,R1,R2 Y R3 TIENEN LOS SIGNIFICADOS QUE SE MUESTRAN EN LA DESCRIPCION), SALES DE EL CON ACIDOS O BASES FARMACEUTICAMENTE ACEPTABLES, UN PROCESO PARA SU PREPARACION Y UNA COMPOSICION FARMACEUTICA CONTENIENDO DICHOS COMPUESTOS O SUS SALES. LOS COMPUESTOS DE FORMULA I Y SUS SALES SE USAN EN EL TRATAMIENTO DEL MAL DE PARKINSON, FALLOS RENALES, FALLOS DE CORAZON E HIPERTENSION.
ES90200937T 1989-04-20 1990-04-17 Profarmaco de dopamina. Expired - Lifetime ES2070994T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT8920209A IT1229853B (it) 1989-04-20 1989-04-20 Farmaci precursori della dopamina.
IT8920210A IT1229854B (it) 1989-04-20 1989-04-20 Farmaci precursori della dopamina.

Publications (1)

Publication Number Publication Date
ES2070994T3 true ES2070994T3 (es) 1995-06-16

Family

ID=26327445

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90200937T Expired - Lifetime ES2070994T3 (es) 1989-04-20 1990-04-17 Profarmaco de dopamina.

Country Status (6)

Country Link
US (1) US5073547A (es)
EP (1) EP0393781B1 (es)
JP (1) JPH02292290A (es)
AT (1) ATE118216T1 (es)
DE (1) DE69016688T2 (es)
ES (1) ES2070994T3 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744485A (en) * 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance
DE19630826A1 (de) * 1996-07-31 1998-02-05 Duro Galvanit Chemie Verfahren zur Aufbereitung von Chlor und gegebenenfalls chlororganische Verbindung enthaltendem Rohwasser, insbesondere Badwasser, sowie Vorrichtung zur Durchführung des vorgenannten Verfahrens
GB9626151D0 (en) * 1996-12-17 1997-02-05 Lilly Industries Ltd Pharmaceutical compounds
DK1044017T3 (da) * 1998-01-05 2008-12-08 Univ Johns Hopkins Kosttilskud til dialysepatienter
WO2004069146A2 (en) * 2003-02-07 2004-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-dopa amide derivatives and uses thereof
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
US7226188B2 (en) * 2004-11-19 2007-06-05 Whiterock Design, Llc Stage lighting methods and apparatus
US8017785B2 (en) * 2006-05-09 2011-09-13 Astrazeneca Ab Salt forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)y1]-4-penten 2-amine
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
EP2112923A1 (en) * 2007-01-22 2009-11-04 Targacept Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
RU2012150449A (ru) 2010-05-20 2014-06-27 Астразенека Аб Новый способ получения арилзамещенных олефиновых аминов
JP6567049B2 (ja) * 2014-10-21 2019-08-28 アッヴィ・インコーポレイテッド カルビドパおよびｌ−ドーパプロドラッグならびにそれらの使用方法
MA41377A (fr) 2015-01-20 2017-11-28 Abbvie Inc Gel intestinal de lévodopa et de carbidona et procédés d'utilisation
EP3445346A1 (en) * 2016-04-20 2019-02-27 AbbVie Inc. Carbidopa and l-dopa prodrugs and methods of use
BR112019014981A2 (pt) 2017-11-24 2020-04-07 H Lundbeck As composto, sal farmaceuticamente aceitável, uso dos mesmos e composição farmacêutica
CN111868071B (zh) 2018-02-08 2024-03-26 耶路撒冷希伯来大学伊森姆研究发展有限公司 新型多巴胺前体
CN110294789A (zh) * 2018-03-21 2019-10-01 海南大学 含多巴寡肽的合成方法及其在抗帕金森病前药方面的应用
US11130775B2 (en) 2019-05-20 2021-09-28 H. Lundbeck A/S Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11168056B2 (en) 2019-05-20 2021-11-09 H. Lundbeck A/S Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol
US11104697B2 (en) 2019-05-20 2021-08-31 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
US11111263B2 (en) 2019-05-20 2021-09-07 H. Lundbeck A/S Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid
JP7562562B2 (ja) 2019-05-21 2024-10-07 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
JP2024509907A (ja) * 2021-03-10 2024-03-05 ニューロデルム，リミテッド レボドパ－チロシンコンジュゲートを含む安定した液体組成物およびそれらの使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3132171A (en) * 1962-06-18 1964-05-05 Strong Cobb Arner Inc 3, 4-diphosphatophenyl-alanine and process for making same
US3891696A (en) * 1973-11-02 1975-06-24 Interx Research Corp Novel, transient pro-drug forms of l-dopa
US4508706A (en) * 1983-03-30 1985-04-02 Yale University Composition for increasing melanin in mammalian skin and hair
US4695449A (en) * 1983-03-30 1987-09-22 Yale University Composition and method for treatment of melanomas
US4618484A (en) * 1983-03-30 1986-10-21 Yale University Composition and method for treatment of melanomas
IT1213182B (it) * 1984-06-25 1989-12-14 Simes Derivati di composti a struttura catecolamminica.
IT1200427B (it) * 1985-03-22 1989-01-18 Afros Spa Procedimento ed impianto per lo stampaggio di pezzi in materiale plastico espanso,con parti o inserti preformati a spruzzo nello stesso stampo di formatura
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa

Also Published As

Publication number Publication date
ATE118216T1 (de) 1995-02-15
EP0393781A3 (en) 1991-01-09
JPH02292290A (ja) 1990-12-03
DE69016688T2 (de) 1995-10-05
US5073547A (en) 1991-12-17
DE69016688D1 (de) 1995-03-23
EP0393781A2 (en) 1990-10-24
EP0393781B1 (en) 1995-02-08

Similar Documents

Publication Publication Date Title
ES2070994T3 (es) Profarmaco de dopamina.
FI893467A0 (fi) Menetelmä lääkeaineena käyttökelpoisten 4-oksokinoliini-3-karboksyylihapon johdannaisten valmistamiseksi
ATE150462T1 (de) Pyrazolopyridinverbindungen und verfahren zu ihrer herstellung
PT87542A (pt) Process for the preparation of a medicament based on indolone derivatives for the treatment of the parkinson disease
PT82610B (pt) Processo para a preparacao de tiazolidino-dionas hipoglicemicas
ATE89547T1 (de) Dopamin-vorlaeufer.
DK232989D0 (da) Antiviralt praeparat
US5330978B1 (en) Phosphonic acid derivatives and use thereof
ES2045067T3 (es) Procedimiento para preparar nuevos compuestos de tiazol.
NO900342D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 3-fenyl-5,6-dihydrobenz(c)acridin-7-carboxylsyrer og beslektede forbindelser.
PT84680A (fr) Procede de preparation de derives 1,5-benzothiazepine et de compositions pharmaceutiques les contenant
PT90635A (pt) Processo para a preparacao de derivados do acido n-(5,6,7,8-tetra-hidropirido-{2,3-d}pirimidin-6-il-alcanoil)glutamico
NO883520L (no) Fremgangsmaate for fremstilling av et injeksjonspreparat.
IE873212L (en) Medicaments based on derivatives of 3,4-di-phenylpiperidine,¹the use of the derivatives as medicaments, and novel¹3,4-diphenylpiperidine derivatives and a process for the¹preparation therefor
DE69627519D1 (de) Sesquiterpen-derivate mit antiviraler aktivität
NO861868L (no) Fremgangsmaate for fremstilling av terapeutisk aktive 1,3-oksatian-derivater.
ATE109454T1 (de) Catecholaminester.
WO1987004435A3 (en) Xanthine compounds
EP0295783A3 (en) A derivative of codeine
AU7506591A (en) A therapeutic agent for dysuria comprising alpha-phenyl-alpha-pyridylalkanoic acid derivatives
FR2655042B1 (fr) Nouvelles benzothiazolinones substituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
RU92004370A (ru) Производные фталазина, способ их получения и лекарственные средства на их основе
WO1988006160A3 (fr) Derives d'acides amines, leur procede de production et compositions pharmaceutiques

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 393781

Country of ref document: ES